How to Cite:

Alradhi, M. S. H., Alghadir, Y. M. A., Alawee, S. S., Mustafa, M. A., & Fenjan, M. F. (2022). Medication-induced hospitalization and clinical pharmacists role regarding, at an al-Basra teaching hospital in Iraq. *International Journal of Health Sciences*, *6*(S4), 11950–11961. https://doi.org/10.53730/ijhs.v6nS4.11448

Medication-induced hospitalization and clinical pharmacists role regarding, at an al-Basra teaching hospital in Iraq

Muhannad Salah Hamza Alradhi

Iraqi Ministry of health, Basrah Health Directorate, Basrah-Iraq Corresponding author email: <u>muhannad.alradhi@gmail.com</u>

Yasameen Mohammed Abbas Alghadir

Iraqi Ministry of health, Basrah Health Directorate, Basrah-Iraq Email: <u>yassminalghadear@gmail.com</u>

Samar Sami Alawee

Iraqi Ministry of health, Al Basrah teaching hospital, Basrah-Iraq Email: angel27924@gmail.com

Mustafa Abdulmohsin Mustafa

Iraqi Ministry of health, Al Basrah teaching hospital, Basrah-Iraq Email: tsummust55@gmail.com

Mohammed Falah Fenjan

Iraqi Ministry of health, Al Basrah teaching hospital, Basrah-Iraq Email: mff8840@gmail.com

Abstract---Study objective: Our objective is to determine the proportion of medication-related problems that lead to patient admission, such as drug interactions, side effects, and drug abuse. The study also aims to evaluate the significance of the clinical pharmacist's contribution to patient care and follow-up regarding the appropriate use of safe and effective treatments. Methods: This study was conducted at al Basra Teaching Hospital. All 115 patients with drug-related hospitalization (DRH) who were admitted between May 1 and June 30, 2022, were included in the study. The patients' ages ranged from 35-75 years, with a median of 52 ± 3.5 years. Hospitalized patients' due to drug-related reasons are as follows: Approximately 32% of cases are antibiotics, 20% are cardio-logical cases, 7.8% are diabetic cases, 13% are monoclonal antibody therapies, 7.8% are NSAIDs, and 19% are other cases. One of three clinical pharmacists with residency training and the attending emergency physician assessed each enrolled patient for the existence or absence of an

International Journal of Health Sciences ISSN 2550-6978 E-ISSN 2550-696X © 2022.

Manuscript submitted: 9 April 2022, Manuscript revised: 18 June 2022, Accepted for publication: 27 July 2022 11950

adverse drug event resulting in hospitalization. Clinical pharmacists collected data on the patient's medication usage, medical history, previous allergies and intolerances, and the complaint they were presenting with. The Basra Teaching Hospital patient care information system and the attending emergency physician provided information on the results of the diagnostic tests. The clinical pharmacist determined whether or not the patient's admission was the result of an adverse drug event after gathering all relevant data on the subject. Results: In this study, 85 women and 30 men were enrolled, and as a result of drug-related problems, the following situations required hospitalization: the percentage of patients who received a diagnosis of an adverse drug event involving DTF is 21.73 %, followed by cases involving contraindications (22.6 %), side effects (26 %), adverse effects (19.13 %), non-compliance (4.35 %), and the same percentage of attempted suicide. Finally, 1.74% was due to a drug interaction. 32% of the studies evaluated admissions due to antibiotic-related problems, 20% of patients' due to problems with antihypertensive medications, and 47% of other factors associated with drug-related hospitalization. In addition. the clinical pharmacist made recommendations to the doctor in this study (30%). Conclusion: According to this study, there were many discovered adverse drug events that led to their admission to the hospital. and here this study emphasized the importance of involving clinical pharmacists in the health care of patients in the hospital emergency department for the purpose of discovering treatment errors and discussing them for the reducing cases of misuse of prescribed drugs.

Keywords---drug related hospitalization, adverse drug events, drug therapeutic failure, clinical pharmacist, drugs, patient compliance, prescription errors.

Introduction

The use of medications is rising globally. This can be explained by the expanding pharmaceutical industry's ability to produce more varieties of drugs and the rising prevalence of ailments that have increased the demand for pharmaceuticals. Medication use can result in a variety of results, from the therapies' anticipated therapeutic effects to mild side effects and even death[1]. The concept "drug related problem" (DRP) refers to an event or condition involving a patient's medication therapy that actually inhibits or may delay the achievement of the desired result. This might be due to poor drug choice, unfavorable drug reactions, untreated indications, drug interactions, insuf ficient dosage, incorrect drug use, and noncompliance. According to reports, DRPrelated admissions have increased over the years [2, 3].

According to estimates, drug-related disorders (DRPs) account for 8.7 million hospital admissions and 17 million emergency room visits annually in the United States. Analyses of studies on DRPs that lead to hospital admission indicate that DRPs account for 5–15% of all hospitalizations, of which 25–75% could have been

11952

avoided. The majority of preventable adverse drug events (ADEs) are linked to medications with constrained therapeutic indices and those that need ongoing, frequent monitoring. Several traits have been noted as potential risk factors for hospital admissions related to drug use. Age, having a wide range of medical specialties, being a woman, and having co-morbidities are a few examples[2, 4]. Hospitalization due to drug use will have detrimental effects on patients and society as a whole. Depending on the contexts, approaches taken, and populations studied, it lowers income and household productivity, raises mortality and morbidity rates, raises health care costs, and lowers quality of life. Various studies conducted around the world revealed varying levels of incidence and preventability of drug-related hospital admissions[4, 5].

These clinical pharmacists can also help patients with recognizing, fixing, and avoiding drug-related issues by offering pharmaceutical care. The influence of clinical pharmacists on incorrect prescribing in hospitalized patients is only partially evaluated by studies that have been specifically developed. Focusing on high-risk populations such patients who use many drugs, which is a significant risk factor for incorrect prescribing, could improve the effectiveness of such as interventions[3, 6, 7]. Additionally, if strategies to enhance prescribing are implemented by a medical professional who closely collaborates with primary care doctors on clinical staff, they may be strengthened. Clinical pharmacists in settings that provide ambulatory care may be in an ideal position to collaborate with medical specialists to reduce inappropriate prescribing[8].

Materials and Method

This study was conducted at al Basra Teaching Hospital. All 115 patients with drug-related hospitalization (DRH) who were admitted between May 1 and June 30, 2022, were included in the study. The patients' ages ranged from (35-75) years, with a median of 52 \pm 3.5 years. Hospitalized patients due to drug-related reasons are as follows: approximately 32% of cases are antibiotics, 20% are cardio-logical cases, 7.8% are diabetic cases, 13% are monoclonal antibody therapies, 7.8% are NSAIDs, and 19% are other cases[9].

Patients were not included in the study if any of the following conditions were met: (1) they left the emergency room before speaking with an emergency doctor or a clinical pharmacist; (2) they were transferred from another hospital for specialized care; or (3) the emergency physician interview and questionnaire were not completed. One of three clinical pharmacists with residency training and the attending emergency physician assessed each enrolled patient for the existence or absence of an adverse drug event resulting in hospitalization. Clinical pharmacists collected data on the patient's medication usage, medical history, previous allergies and intolerances, and the complaint they were presenting with. The Basra Teaching Hospital patient care information system and the attending emergency physician provided information on the results of the diagnostic tests. The clinical pharmacist determined whether or not the patient's admission was the result of an adverse drug event after gathering all relevant data on the subject[10]. The adverse drug events considered were either dose-related therapeutic failure (DTF), which means a lack of therapeutic effect caused by drug noncompliance, a too-low dose prescribed, interaction, recent dose reduction/discontinuation, or insufficient monitoring[11]. In the basic intervention group, a clinical pharmacist started an organized, patient medication review as soon as the patient was admitted, when laboratory data became available, and when the primary medical admission report was finished. The effectiveness of each medication on the medication list was assessed based on its indication for use, dosage (taking renal failure, age, and other factors into consideration), adverse drug events, therapeutic duplication, dosage time and interval, formulation and strength, contraindications, interactions. precautions. and unique patient characteristics[3].

Following the medication review, our participating pharmacists were not allowed to change the patient's medications. however, they did record possible alterations. A clinical pharmacist filled out the patient's data (clinical pharmacist intervention sheet) and, if possible, spoke with the patient's doctor, who would then accept or reject the advice[12]. Within the first two days of admission, and rarely after, the patients were contacted by a clinical pharmacist trainee. A thorough drug history was taken, with particular focus on the previous 14 days. When necessary, additional information was gathered from family members, home nurses, doctors, or other sources[9]. Among the topics covered in the interview were dose adjustments, new medications, drug discontinuation, drug administration, adverse drug events, adherence, and cost. Motivational interviewing is a coaching technique that aims to ensure adequate patient behavior in order to reduce adverse drug reactions and other drug-related concerns. All interventions were carried out by clinical pharmacists who had been trained. Three distinct pharmacists were involved in data collection during the study, though not at the same time due to employment changes and other factors. Furthermore, all pharmacists were educated in medication review workshops and had completed a 2-day training in motivational interviewing with the following practice sessions prior to participating in the study[3]. On the basis of written and verbal information, every patient contacted agreed to participate. The regional ethics committee also approved the study[13].

Data extraction

Study area, study design, subjects, sample size, main findings (frequency of hospital admission and death due to drug-related problems, type, severity, casualty and preventability of DRPs, drugs and drug classes responsible for admission, and factors associated with drug-related admission) and study characteristics (study area, study design, subjects, and sample size) were all taken from Al Basra teaching hospital by clinical pharmacist trainees.

Statistical analysis

The data was statistically analyzed using percentages, frequencies, and mean standard deviation as required. P values lower than 0.05 were considered statistically significant. The 19.0 version of the Predictive Analytics software was used.

11954

Result

Regarding the 115 patients who were admitted, shown in Figure 1 as 85 women and 30 men, as a result of drug-related problems, the following situations required hospitalization. Figure 3 shows that the percentage of patients who received a diagnosis of an adverse drug event involving DTF is 21.73%, followed by cases involving contraindications (22.6%), side effects (26%), adverse effects (19.13%), non-compliance (4.35%), as well as the same percentage of attempted suicide, and finally 1.74% related to drug interaction. As shown in Table 1, and Figure 2, which depicts the baseline characteristics of the patients included in the study, 32% of the studies assessed admissions due to problems related to antibiotics, 20% of patients related to problems with antihypertensive medications, and a reminder, 47% of other factors that are associated with drugrelated hospitalization.

Clinical pharmacists at the hospital offered interventions to doctors regarding drug-drug interactions, dosing, ADR, DTF, and drug abuse Some of these interventions, such as aspirin and mefenamic acid, were prescribed to nine patients (7.8%), causing GIT bleeding. Other examples from other groups include vancomycin as a cause of red man syndrome (13%) and lisinopril with aspirin as a drug drug interaction (17.4%) of the study sample. Therapy failure due to patient misuse, such as glimepiride (33.3%)[3].

Additionally, in this study, the clinical pharmacist made recommendations to the doctor (30%), for example, advising adding propranolol to the treatment plan for a patient who was experiencing arrhythmia as a side effect of taking methylprednisolone, increase the dose of methyldopa after low dose therapeutic failure in first trimester pregnant lady.



Figure 1: Gender graph (n=115).



Figure 2: Characteristics of drug-related hospitalizations (n=115)

Table 1: Characteristics of patients admitted to hospitals for drug-related reasons and the intervention of clinical pharmacists (n=115)

Drug	n	DRH (symptom)	Mechanism	Clinical Pharmacist
Venofere	1	Allergic reaction, hypotension and	Adverse drug reaction	Add hydrocortisone, slow infusion
Olan	2	Tardive dyskinesia	Contraindication	Stop Olan
Citalopram	1	Serotonin syndrome	Contraindication	Stop citalopram
Diazepam	4	suicidal attempt	suicide attempt	Given antidote
Ferrous sulphate	1	GIT discomfort, dyspepdia	Side effect	Change to ferrous gluconate
Prednisolone	1	steroid induced oral candidiasis	side effect	use nystatin oral drop
levetiracetam	1	sleepiness and decrease consciousness	Side effect	Dose reduction
Metoclopramide	3	contraindicated with colostomy	Contraindication	use ondansetron amp.
Biotin	1	False TSH result and misdiagnosis due to prolonged use	Drug therapeutic failure	stop biotin
Methylprednisolone	3	arrhythmia	Adverse drug reaction	add propranolol
Tramadol	2	acute dystonic reaction	Contraindication	stop tramadol, add nefopam on need
Iron	1	misuse in thalacemic patient	Drug therapeutic failure	stop iron, use deferoxamine inj.
Clonazepam	1	suicidal attempt	suicide attempt	Given antidote

1	1956

Metformin	2	failure of therapy due to patient incompliance	Drug therapeutic failure	change to insulin therapy
Glimepiride	3	failure of therapy due to patient misuse	Drug therapeutic failure	change to insulin therapy
Pioglitazone	2	failure of therapy due to patient misuse	Drug therapeutic failure	change to insulin therapy
Insulin	2	failure of therapy due to misuse	Drug therapeutic failure	Adjust insulin dose
Rosuvastatin	1	Rhabdomyolysis	Contraindication	Stop statin, change to fenofibrate
Lasix	2	Gentamycin Lasix contraindication	contraindication	change to ceftriaxone
Methyldopa	1	therapeutic failure	Drug therapeutic failure	increase dose
Lisinopril	4	contraindicated with aspirin	contraindication	use ARABS type antihypertensive
Spironolactone	3	arrhythmia	adverse drug reaction	add propranolol
Anticoagulants	1	therapeutic failure	Drug therapeutic failure	add clexane
Heparin	2	thrombocytopenia	adverse drug reaction	change to clexane
Plavix	1	nose bleeding	Side effect	Dose reduction
Dopamine	1	contraindicated with uncorrected ventricular fibrillation	contraindication	use noradrenaline
Propranolol	2	bronchospasm	drug interaction	stop propranolol
Salbutamol	1	tachycardia	Side effect	dose reduction
Enoxaparin	3	bruise	side effect	change the site of injection
Digoxin	1	contraindicated with omeprazole	contraindication	stop omeprazole
Rituximab	3	Hypotension	adverse drug reaction	Add hydrocortisone to the therapy
Immunoglobulin	4	rash, dyspnea	Side effect	slow infusion time
Cyclophsphamide	2	Rash, dyspnea, hyperthermia	Side effect	Add mesna, increase fluid intake, slow infusion rate
Tysabri	2	JCV positive	contraindication	Stop Tysabri, use steroids
Fingolamod	5	incompatibility	non-compliance	change to tysabri
Aspirin	4	GIT bleeding	Side effect	Stop aspirin, add omeprazole 5 vials for 3 days.

Diclofenac2contraindicated in asthmatic patientscontraindicationuse paracetamol asthmatic patientsMefenamic acid1GIT lesionDrug therapeutic failureuse misoprostolIndomethacin1peptic ulcerSide effectuse misoprostollyophilized2nosebleeding, vash, tachycardia, dyspnea, electrolyte imbalanceSide effectuse misoprostolVancomycin5Red man syndrome vomitingDrug therapeutic failureslow the infusion timeAugmentin2diarrhea, nausea, vomitingSide effectAdd enetrogerminaCiprofloxacin3Thalacemic crisis reactioncontraindication adverse drug reactionStop ciprofloxacinFirst line anti TB1FailureDrug therapeutic failurechange to second lineAll antibiotics used1Vaginal thrush adverseadverse drug reactionMonitoring reactionMeropenem1Under therapeutic failureincrease dose therapeutic failureincrease dose therapeutic failureAll antibiotics used1Vaginal thrush adversedid clotrimazole cream reactionMeropenem1genicilin allergy vomiting, bitterSide effectadd add clotrimazole cream reactionAmbycicilin1penicillin allergy vomiting, bitterSide effectadd contraindicationAttraste0norder vomiting, bittercontraindication reactionUse ceftriaxone vial therapeutic failu	Ibuprofen	1	Sickle cell crisis	contraindication	Stop Ibuprofen
Mefenamic acid1GIT lesionDrug therapeutic failureuse misoprostolIndomethacin1peptic ulcerSide effectuse misoprostolIyophilized2nosebleeding, rash, tachycardia, dyspnea, electrolyteSide effectuse misoprostolVancomycin5Red man syndrome mbalanceDrug therapeutic failureslow the infusion timeAugmentin2diarthea, nausea, vomitingSide effectAdd enetrogermina vomitingCiprofloxacin3Thalacemic crisis reactioncontraindication reactionStop ciprofloxacin allermine, zantac amp.First line anti TB1FailureDrug therapeutic failureAdd enetrogermina vomitingClofazamine1Brownish skin adverseadverse drug reactionMonitoring reactionAll antibiotics used1Vaginal thrush adverseadverse drug therapeutic failureadd clotrimazole cream reactionAmoxicillin1penicillin allergySide effectadd clotrimazole cream contraindicationMeropenem1Under therapeutic failureadd clotrimazole cream reactionAmoxicillin1penicillin allergySide effectadd clotrimazole cream contraindicationAmikacin3contraindicated in contraindicationuse effriaxone41penicillin allergySide effectadd clotrimazole cream contraindicationMeropenem1penicillin allergySide effectadd	Diclofenac	2	contraindicated in	contraindication	use paracetamol
Melenamic acid1GIT lesionDrug therapeutic failureuse misoprostolIndomethacin1peptic ulcerSide effectuse misoprostolIndomethacin2nosebleeding, rash, tachycardia, dyspnea, electrolyteSide effectuse misoprostolVancomycin5Red man syndromeDrug therapeutic failureslow the infusion timeAugmentin2diarrhea, nausea, vomitingSide effectAdd enetrogerminaCiprofloxacin3Thalacemic crisis reactioncontraindicationStop ciprofloxacinLevofloxacin3Anaphylactic reactionadversedrug therapeutic failureAdd hydrocortisone, allermine, zantac amp.First line anti TB1FailureDrug therapeutic failurechange to second lineAll antibiotics used1Vaginal thrush doseadversedrug therapeutic failureMeropenem1Under therapeutic doseDrug therapeutic failureincrease doseMeropenem1Penicillin allergySide effectadd clotrimazole cream reactionMetronidazole2vaginal thrush adverseadverse drug therapeutic failureadd change to second lineMetronidazole2vaginal thrush adverseadverse drug therapeutic failureadd change to gentanycinAll antibiotics used1Under therapeutic failurechange to gentanycin coseceterionAmoxicillin1penicillin aller			asthmatic patients	_	
Indomethacin1peptic ulcerSide effectuse misoprostolIyophilized2nosebleeding, rash, tachycardia, dyspnea, electrolyteSide effectchange amphotericin B to posacanazole tab.Vancomycin5Red man syndromeDrug therapeutic failureslow the infusion timeAugmentin2diarrhea, nausea, vomitingSide effectAdd enetrogerminaCiprofloxacin3Thalacemic crisiscontraindicationStop ciprofloxacinLevofloxacin3Thalacemic crisiscontraindicationStop ciprofloxacinLevofloxacin3Thalacemic crisiscontraindicationStop ciprofloxacinIcorofloxacin3Anaphylacticadversedrug therapeutic failureFirst line anti TB1FailureDrug therapeutic failurechange to second lineAll antibiotics used1Vaginal thrush pigmentation reactionadversedrug duringMeropenem1Under therapeutic failureincrease doseAmoxicillin1penicillin allergy vomiting,Side effectadd clotrimazole cream reactionAmikacin3contraindicated in Myasthenia Gravisside effectdadd hydrocortisone, allermine, change to gentamycinMetronidazole2nausea andadverse drug reactionadd clotrimazole cream reactionAmikacin3contraindicated in Myasthenia Gravisside effectdose reductionMetronidazole2nausea	Metenamic acid	1	GIT lesion	Drug	use misoprostol
Indomethacin1peptic ulcerSide effectuse misoprostollyophilized2nosebleeding, rash, tachycardia, dyspnea, electrolyte imbalanceSide effectchange amphotericin B to posacanazole tab.Vancomycin5Red man syndrome therapeutic failureDrug therapeutic failureslow the infusion timeAugmentin2diarrhea, nausea, vomitingSide effectAdd enetrogermina vomitingCiprofloxacin3Thalacemic crisis reactioncontraindicationStop ciprofloxacin adverseFirst line anti TB1FailureDrug therapeutic failurechange to second line therapeutic failureClofazamine1Brownish pigmentationadversedrug reactiondol clotrimazole cream reactionAll antibiotics used1Vaginal thrush adverseadd clotrimazole cream reactionadd clotrimazole cream reactionMeropenem1Under therapeutic failureDrug therapeutic failureincrease dose therapeutic failureAmoxicillin1pencillin allergySide effectadd clotrimazole cream reactionAmoxicillin1pencillin allergySide effectadd clotrimazole cream reactionAmoxicillin1pencillin allergySide effectadd clotrimazole cream reactionAmoxicillin1pencillin allergySide effectdose reductionAmixacin3contraindicated in Myasthenia GravisSide effectdose reduction				failure	
Ivophilized Amphotericin B2nose bleeding, rash, tachycardia, dyspnea, electrolyte imbalanceSide effectchange amphotericin B to posacanazole tab.Vancomycin5Red man syndrome imbalanceDrug therapeutic failureslow the infusion time therapeutic failureAugmentin2diarrhea, nausea, vomitingSide effectAdd enetrogerminaCiprofloxacin3Thalacemic crisis reactioncontraindicationStop ciprofloxacinLevofloxacin3Anaphylactic reactionadversedrug therapeutic failureAdd hydrocortisone, allermine, zantac amp.First line anti TB1FailureDrug therapeutic failurechange to second lineAll antibiotics used1Vaginal thrush vaginal thrushadversedrug reactionMeropenem1Under therapeutic failureincrease dose therapeutic failureincrease doseMeropenem1penicillin allergySide effectadd hydrocortisone, allermine, change to gentamycinCeftriaxone5Vaginal thrush masteria Gravisadversedrug add clotrimazole cream reactionMetronidazole2nausea nausea and yasthenia GravisSide effectadd hydrocortisone, allermine, change to gentamycinMetronidazole3contraindicated in Myasthenia Gravisside effectdose reduction due to misuseMetronidazole2nausea nausea andside effectdose reductionMetronidazole<	Indomethacin	1	peptic ulcer	Side effect	use misoprostol
Amphotericin Brash, tachycardia, dyspnea, electrolyte imbalanceposacanazole tab.Vancomycin5Red man syndrome imbalanceDrug therapeutic failureslow the infusion timeAugmentin2diarrhea, nausea, vomitingSide effectAdd enetrogerminaCiprofloxacin3Thalacemic crisis reactioncontraindication reactionStop ciprofloxacin allermine, zantac amp.First line anti TB1FailureDrug reactionchange to second line therapeutic failureClofazamine1Brownish skin pigmentation reactionadverse reactiondrug reactionAll antibiotics used1Vaginal thrush doseadverse drug therapeutic failuremonitoring reactionMeropenem1Under therapeutic failureDrug therapeutic failureincrease dose therapeutic failureAmoxicillin1penicillin allergySide effectadd hydrocortisone, allermine, change to gentamycinAmoxicillin1penicillin allergySide effectadd doseAmikacin3contraindicated in Myasthenia GraviscontraindicationUse ceftriaxoneMetronidazole2nausea nauseSide effectdose reductionAzithromycin tab1therapeutic failureSide effectdose reductionAmixacin3contraindicated in Myasthenia GravisSide effectdose reductionAzithromycin tab1therapeutic failureSide effect <t< td=""><td>lyophilized</td><td>2</td><td>nose bleeding,</td><td>Side effect</td><td>change amphotericin B to</td></t<>	lyophilized	2	nose bleeding,	Side effect	change amphotericin B to
Vancomycin5Red man syndrome imbalanceDrug therapeutic failureslow the infusion time therapeutic failureAugmentin2diarrhea, nausea, vomitingSide effectAdd enetrogerminaCiprofloxacin3Thalacemic crisiscontraindicationStop ciprofloxacin3Anaphylactic reactionadversedrug duret herapeutic failureAdd hydrocortisone, allermine, zantac amp.First line anti TB1FailureDrug therapeutic failurechange to second lineClofazamine1Brownish skin adverseadversedrug add clotrimazole cream reactionAll antibiotics used1Vaginal thrush doseadversedrug add clotrimazole cream reactionMeropenem1Under therapeutic doseincrease dose therapeutic failureadd clotrimazole cream reactionAmoxicillin1penicillin allergySide effectadd clotrimazole cream reactionAmikacin3contraindicated in Myasthenia Graviscontraindicated in Myasthenia Graviscontraindicated in Myasthenia GravisMetronidazole2nausea rash, tachycardia, dyspnea, electionSide effectdose reductionJyophilized3nosebleeding, side effectchange to ceftriaxone vialAmikacin3noseSide effectchange to ceftriaxone vialAmikacin3nosebleeding, side effectchange to ceftriaxone vialApplitized3nose <t< td=""><td>Amphotericin B</td><td></td><td>rash, tachycardia,</td><td></td><td>posacanazole tab.</td></t<>	Amphotericin B		rash, tachycardia,		posacanazole tab.
Vancomycin5Red man syndrome herapeutic failureDrug therapeutic failureslow the infusion timeAugmentin2diarrhea, nausea, vomitingSide effectAdd enetrogerminaCiprofloxacin3Thalacemic crisiscontraindicationStop ciprofloxacin1Thalacemic crisiscontraindicationStop ciprofloxacin2diarrhea, nausea, vomitingadversedrug Addhydrocortisone, allermine, zantac amp.First line anti TB1FailureDrug therapeutic failurechange to second lineClofazamine1Brownish skin pigmentation reactionadversedrug add clotrimazole cream reactionAll antibiotics used1Vaginal thrush doseadversedrug therapeutic failureadd clotrimazole cream reactionAmoxicillin1penicillin allergySide effectadd add hydrocortisone, allermine, change to gentamycinCeftriaxone5Vaginal thrush novinting, bitter tastecontraindicated in mysthenia Graviscontraindication therapeutic failureAmikacin3contraindicated in vomiting, bitter tasteSide effectdose reductionAzithromycin tab1therapeutic failure tasteSide effectdose reductionAzithromycin tab1nosebleeding, rash, tachycardia, dyspnea, electrolyteSide effectchange to ceftriaxone vial therapeutic failureJophilized3nosebleeding, rash, tachycardia, dy			dyspnea,		
Vancomycin5Red man syndrome med man syndromeDrug therapeutic failureslow the infusion timeAugmentin2diarrhea, nausea, vomitingSide effectAdd enetrogerminaCiprofloxacin3Thalacemic crisiscontraindicationStop ciprofloxacinIevofloxacin3Anaphylactic reactionadversedrug allermine, zantac amp.First line anti TB1FailureDrug reactionchange to second lineFirst line anti TB1Brownish skin pigmentationadversedrug reactionAll antibiotics used1Vaginal thrush vomicadversedrug therapeutic failureAll antibiotics used1Under therapeutic doseDrug therapeutic failureincrease doseMeropenem1penicillin allergySide effectadd clotrimazole cream reactionAmoxicillin1penicillin allergySide effectadd clotrimazole cream reactionAmikacin3contraindicated in Myasthenia Graviscontraindicationadd clotrimazole creamMetronidazole2nausea a and vomiting, bitter tasteSide effectdose reductionAzithromycin tab1therapeutic failurechange to ceftriaxone vial therapeutic failureAzithromycin B3nosebleeding, rash, tachycardia, dyspnea, electrolyteSide effectchange to ceftriaxone vial			imbalance		
Augmentin2diarrhea, nausea, ountingSide effectAdd enetrogerminaAugmentin2diarrhea, nausea, ountingSide effectAdd enetrogerminaCiprofloxacin3Thalacemic crisiscontraindicationStop ciprofloxacinIevofloxacin3AnaphylacticadversedrugAddhydrocortisone, allermine, zantac amp.First line anti TB1FailureDrug therapeutic failurechange to second lineClofazamine1Brownish skin pigmentationadversedrugadd clotrimazole creamAll antibiotics used1Vaginal thrush doseadversedrug therapeutic failureincrease doseMeropenem1Under therapeutic doseDrug therapeutic failureincrease doseAmoxicillin1penicillin allergySide effectadd hydrocortisone, allermine, change to gentamycinCeftriaxone5Vaginal thrush mastenia Gravisadverse drug reactionadd clotrimazole creamAmikacin3contraindicated in mysathenia GraviscontraindicationUse ceftriaxoneAzithromycin tab1therapeutic failure tasteSide effectdose reductionIyophilized Amphotericin B3nose bleeding, rash, tachycardia, dyspnea, electrolytreSide effectchange to ceftriaxone vialIpophilized3nose bleeding, rash, tachycardia, dyspnea, electrolytreSide effectchange to ceftriaxone vial	Vancomycin	5	Red man syndrome	Drug	slow the infusion time
Augmentin2diarthea, nausea, vomitingSide effectAdd enetrogerminaAugmentin2diarthea, nausea, vomitingSide effectAdd enetrogerminaCiprofloxacin3Thalacemic crisiscontraindicationStop ciprofloxacinLevofloxacin3AnaphylacticadversedrugAddFirst line anti TB1FailureDrug therapeutic failurechange to second lineFirst line anti TB1BrownishskinadversedrugClofazamine1BrownishskinadversedrugMeropenem1Vaginal thrushadversedrugincrease doseMeropenem1Under therapeutic doseDrug therapeutic failureincrease doseAmoxicillin1penicillin allergySide effectadd clotrimazole cream allermine, change to gentamycinCeftriaxone5Vaginal thrushadversedrug reactionadd hydrocortisone, allermine, change to gentamycinMetronidazole2nausea and yosthenia GravisSide effectdose reductionMetronidazole2nausea reactionSide effectdose reductionAzithromycin tab1therapeutic failure due to misuseDrug reactionchange to ceftriaxone vial therapeutic failureMetronidazole3nosebleeding, rash, tachycardia, dyspnea, electrolyteSide effectchange amphotericin B to liposomal type.	5		5	therapeutic	
Augmentin2diarrhea, nausea, vomitingSide effectAdd enetrogerminaCiprofloxacin3Thalacemic crisiscontraindicationStop ciprofloxacinLevofloxacin3Anaphylactic reactionadversedrug reactionAddFirst line anti TB1FailureDrug therapeutic failurechange to second lineClofazamine1Brownishskin pigmentationadversedrug reactionMonitoringAll antibiotics used1Vaginal thrush doseadversedrug reactionincrease doseMeropenem1Under therapeutic doseDrug reactionincrease doseAmoxicillin1penicillin allergySide effect adverseadd clotrimazole cream reactionAmikacin3contraindicated in Myasthenia Graviscontraindicated in therapeutic failureadd clotrimazole cream gentamycinAmikacin3contraindicated in Myasthenia Graviscontraindicated in therapeutic failureUse ceftriaxoneAzithromycin tab1therapeutic failure due to misuseSide effect failuredose reductionIyophilized Amphotericin B3nose reactionSide effect failurechange to ceftriaxone vial therapeutic failureIyophilized Amphotericin B3nose reactionSide effect failurechange amphotericin B to liposomal type.				failure	
Ciprofloxacin3Thalacemic crisis crisiscontraindication adverseStop ciprofloxacinLevofloxacin3Anaphylactic reactionadverse reactiondrug Add hydrocortisone, allermine, zantac amp.First line anti TB1FailureDrug therapeutic failurechange to second lineFirst line anti TB1Brownish pigmentationadverse reactiondrug therapeutic failurechange to second lineClofazamine1Brownish pigmentationadverse reactiondrug reactionadd clotrimazole cream reactionAll antibiotics used1Vaginal thrush doseadverse therapeutic failureadd clotrimazole cream reactionMeropenem1Under therapeutic doseDrug therapeutic failureincrease doseAmoxicillin1penicillin allergySide effectadd hydrocortisone, allermine, change to gentamycinCeftriaxone5Vaginal thrush mysthenia Gravisadverse reactiondug therapeutic failureMetronidazole2nausea nausea tasteSide effectdose reductionMetronidazole2nausea rash, tachycardia, dyspnea, electrolyteDrug therapeutic failurechange to ceftriaxone vial therapeutic failureIyophilized Amphotericin B3nose rash, tachycardia, dyspnea, electrolyteSide effectchange amphotericin B to liposomal type.	Augmentin	2	diarrhea, nausea,	Side effect	Add enetrogermina
Clipfoloxacin3Anaphylactic reactionadverse reactiondrug reactionAdd allermine, zantac amp.First line anti TB1FailureDrug therapeutic failurechange to second lineClofazamine1Brownish pigmentationDrug reactionchange to second lineAll antibiotics used1Vaginal thrush doseadverse reactiondud clotrimazole cream reactionAll antibiotics used1Under therapeutic doseDrug reactionincrease doseMeropenem1Under therapeutic dosebrug therapeutic failureincrease doseAmoxicillin1penicillin allergySide effectadd clotrimazole cream reactionAmoxicillin1penicillin allergySide effectadd clotrimazole cream reactionAmikacin3contraindicated in Myasthenia GraviscontraindicationUse ceftriaxoneMetronidazole2nausea u due to misuseSide effectdosedoseAzithromycin tab1therapeutic failure due to misuseDrug therapeutic failurechange to ceftriaxone vial therapeutic failureIyophilized Amphotericin B3nose pleeding, rash, tachycardia, dyspnea, electrolyteSide effectchange amphotericin B to liposomal type.	Ciproflovacin	3	Vomiting Thelecemic crisis	contraindication	Stop ciproflovacin
Action and iterationiteractionreactionreactionallermine, gantac amp.First line anti TB1FailureDrug therapeutic failurechange to second lineClofazamine1Brownishskin pigmentationadversedrugMonitoringAll antibiotics used1Vaginal thrush 	Levofloxacin	3	Anaphylactic	adverse drug	Add hydrocortisone
First line anti TB1FailureDrug therapeutic failurechange to second lineClofazamine1Brownish skin pigmentationadverse reactionMonitoringAll antibiotics used1Vaginal thrush doseadverse reactiondrug reactionadd clotrimazole cream reactionMeropenem1Under therapeutic doseDrug therapeutic failureincrease doseAmoxicillin1penicillin allergySide effectadd hydrocortisone, allermine, change to gentamycinCeftriaxone5Vaginal thrush makacinadverse nectiondrug sectionAmikacin3contraindicated in Myasthenia Graviscontraindication therapeutic failureUse ceftriaxoneMetronidazole2nausea nusseSide effectdose reductionAzithromycin tab1therapeutic failure due to misuseDrug therapeutic failurechange to ceftriaxone vial therapeutic failureIyophilized Amphotericin B3nose pleeding, rash, tachycardia, dyspnea, electrolyteSide effectchange amphotericin B to liposomal type.	Levonoxueni	Ŭ	reaction	reaction	allermine, zantac amp.
ClofazamineIBrownish skin pigmentation reactionadverse reactiondrug meactionMonitoringAll antibiotics used1Vaginal thrush adverseadverse reactiondrug add clotrimazole cream reactionadd clotrimazole cream reactionMeropenem1Under therapeutic doseDrug therapeutic failureincrease doseAmoxicillin1penicillin allergySide effectadd hydrocortisone, allermine, change to gentamycinCeftriaxone5Vaginal thrush myasthenia Gravisadverse drug reactionadd clotrimazole cream reactionMetronidazole2nausea and vomiting, bitter tasteSide effectdose reductionAzithromycin tab1therapeutic failure due to misuseSide effectdose reductionIyophilized Amphotericin B3nose bleeding, rash, tachycardia, dyspnea, electrolyteSide effectchange amphotericin B to liposomal type.	First line anti TB	1	Failure	Drug	change to second line
Clofazamine1Brownish <skin </skin pigmentationadverse reactiondrug reactionAll antibiotics used1Vaginal thrush adverseadverse reactionadd clotrimazole cream reactionMeropenem1Under therapeutic doseDrug therapeutic failureincrease doseAmoxicillin1penicillin allergySide effect reactionadd clotrimazole cream allermine, change to gentamycinAmoxicillin1penicillin allergy reactionSide effect reactionadd clotrimazole cream allermine, change to gentamycinCeftriaxone5Vaginal thrush myasthenia Gravisadverse contraindicated in Myasthenia Graviscontraindication myasthenia GravisUse ceftriaxoneMetronidazole2nausea tasteSide effect contraindicationdose reductionAzithromycin tab1therapeutic failure due to misuseDrug therapeutic failurechange to ceftriaxone vial therapeutic failureIyophilized Amphotericin B3nose bleeding, rash, tachycardia, dyspnea, electrolyteSide effectchange amphotericin B to liposomal type.				therapeutic	
Clotazamine1Brownish pigmentationskin reactionadverse reactiondrug reactionMonitoringAll antibiotics used1Vaginal thrush vaginal thrushadverse adversedrug add clotrimazole cream increase doseMeropenem1Under therapeutic doseDrug therapeutic failureincrease doseAmoxicillin1penicillin allergySide effectadd clotrimazole cream gentamycinAmoxicillin1penicillin allergySide effectadd clotrimazole cream gentamycinCeftriaxone5Vaginal thrush vasthenia Gravisadverse reactionadd clotrimazole cream reactionMetronidazole2nausea vasthenia GravisSide effectdose reductionMetronidazole1therapeutic failure due to misuseDrug therapeutic failurechange to ceftriaxone vial therapeutic failureAzithromycin tab1therapeutic failure due to misuseDrug therapeutic failurechange to ceftriaxone vial therapeutic failureIyophilized Amphotericin B3nose pleed, rash, tachycardia, dyspnea, electrolyteSide effectchange amphotericin B to liposomal type.		1	D 11 11	failure	
All antibiotics used1Vaginal thrush Vaginal thrushadverse adversedrug reactionadd clotrimazole creamMeropenem1Under therapeutic doseDrug therapeutic failureincrease doseAmoxicillin1penicillin allergySide effectadd hydrocortisone, allermine, change to gentamycinCeftriaxone5Vaginal thrushadverse reactiondrug therapeutic failureAmikacin3contraindicated in Myasthenia GraviscontraindicationUse ceftriaxoneMetronidazole2nausea tasteSide effectdose reductionAzithromycin tab1therapeutic failure due to misuseDrug therapeutic failurechange to ceftriaxone vial therapeutic failureIyophilized Amphotericin B3nose reak pleeding, rash, tachycardia, dyspnea, electrolyteSide effectchange amphotericin B to liposomal type.	Cloiazamine	1	Brownish skin	adverse drug	Monitoring
Meropenem1Under therapeutic doseDrug therapeutic failureincrease doseAmoxicillin1penicillin allergySide effectadd hydrocortisone, allermine, change to gentamycinCeftriaxone5Vaginal thrushadverse drug reactionadd clotrimazole creamAmikacin3contraindicated in Myasthenia GraviscontraindicationUse ceftriaxoneMetronidazole2nausea and vomiting, bitter tasteSide effectdose reductionAzithromycin tab1therapeutic failure due to misuseDrug therapeutic failurechange to ceftriaxone vial therapeutic failureIyophilized Amphotericin B3nose bleeding, rash, tachycardia, dyspnea, electrolyteSide effectchange amphotericin B to liposomal type.	All antibiotics used	1	Vaginal thrush	adverse drug	add clotrimazole cream
Meropenem1Under therapeutic doseDrugincrease doseAmoxicillin1penicillin allergySide effectadd hydrocortisone, allermine, change to gentamycinAmoxicillin1penicillin allergySide effectadd clotrimazole cream reactionCeftriaxone5Vaginal thrushadverse drug reactionadd clotrimazole cream reactionAmikacin3contraindicated in Myasthenia GraviscontraindicationUse ceftriaxoneMetronidazole2nausea and vomiting, bitter tasteSide effectdose reductionAzithromycin tab1therapeutic failure due to misuseDrug therapeutic failurechange to ceftriaxone vial therapeutic failureIyophilized3nose bleeding, rash, tachycardia, dyspnea, electrolyteSide effectchange amphotericin B to liposomal type.				reaction	
Amoxicillin1penicillin allergy penicillin allergySide effect add hydrocortisone, allermine, change to gentamycinCeftriaxone5Vaginal thrush reactionadd clotrimazole cream reactionAmikacin3contraindicated in Myasthenia Graviscontraindication side effectUse ceftriaxoneMetronidazole2nausea vomiting, bitter tasteSide effectdose reductionAzithromycin tab1therapeutic failure due to misuseDrug therapeutic failurechange to ceftriaxone vial therapeutic failureIyophilized Amphotericin B3nose rash, tachycardia, dyspnea, electrolyteSide effectchange amphotericin B to liposomal type.	Meropenem	1	Under therapeutic	Drug	increase dose
Amoxicillin1penicillin allergySide effectadd hydrocortisone, allermine, change to gentamycinCeftriaxone5Vaginal thrushadverse drug reactionadd clotrimazole cream reactionAmikacin3contraindicated in Myasthenia GraviscontraindicationUse ceftriaxoneMetronidazole2nausea and vomiting, bitter tasteSide effectdose reductionAzithromycin tab1therapeutic failure due to misuseDrug therapeutic failurechange to ceftriaxone vial therapeutic failureIyophilized Amphotericin B3nose bleeding, rash, tachycardia, dyspnea, electrolyteSide effectchange amphotericin B to liposomal type.			dose	therapeutic	
Amoxicum1penicum anergyside enectaddnythocortisone, allermine, change to gentamycinCeftriaxone5Vaginal thrushadverse drug reactionadd clotrimazole creamAmikacin3contraindicated in Myasthenia GraviscontraindicationUse ceftriaxoneMetronidazole2nausea and vomiting, bitter tasteSide effectdose reductionAzithromycin tab1therapeutic failure due to misuseDrug therapeutic failurechange to ceftriaxone vialIyophilized3nose bleeding, rash, tachycardia, dyspnea, electrolyteSide effectchange amphotericin B to liposomal type.	Amovioillin	1	nonicillin ollorgy	failure Side offect	add bydragartigang
Ceftriaxone5Vaginal thrush adverse reactionadverse reactiondrug 	AIIIOXICIIIII	1	periferini anergy	Side ellect	allermine, change to
Ceftriaxone5Vaginal thrush adverseadverse drug reactiondd clotrimazole cream add clotrimazole creamAmikacin3contraindicated in Myasthenia GraviscontraindicationUse ceftriaxoneMetronidazole2nausea vomiting, bitter tasteSide effectdose reductionAzithromycin tab1therapeutic failure due to misuseDrug therapeutic failurechange to ceftriaxone vialIyophilized Amphotericin B3nose pleeding, dyspnea, electrolyteSide effectchange amphotericin B to liposomal type.					gentamycin
Amikacin3contraindicated in Myasthenia Graviscontraindication contraindicationUse ceftriaxoneMetronidazole2nausea and vomiting, bitter tasteSide effectdose reductionAzithromycin tab1therapeutic failure due to misuseDrug therapeutic failurechange to ceftriaxone vial therapeutic failureIyophilized3nose bleeding, rash, tachycardia, dyspnea, electrolyteSide effectchange amphotericin B to liposomal type.	Ceftriaxone	5	Vaginal thrush	adverse drug	add clotrimazole cream
Amikacin3contraindicated in Myasthenia GraviscontraindicationUse celtriaxoneMetronidazole2nausea and vomiting, bitter tasteSide effectdose reductionAzithromycin tab1therapeutic failure due to misuseDrug therapeutic failurechange to ceftriaxone vial therapeutic failureIyophilized3nose bleeding, rash, tachycardia, dyspnea, electrolyteSide effectchange amphotericin B to liposomal type.	A '1 '	0		reaction	
Mydshieling GravisSide effectdose reductionMetronidazole2nausea and vomiting, bitter tasteSide effectdose reductionAzithromycin tab1therapeutic failure due to misuseDrug therapeutic failurechange to ceftriaxone vialIyophilized3nose bleeding, rash, tachycardia, dyspnea, electrolyteSide effectchange amphotericin B to liposomal type.	Amikacin	3	Contraindicated in Myasthenia Gravis	contraindication	Use celtriaxone
Azithromycin tab1therapeutic failure due to misuseDrug therapeutic failurechange to ceftriaxone viallyophilized3nose bleeding, 	Metronidazole	2	nausea and	Side effect	dose reduction
Azithromycin tab1tasteDrug therapeutic failure due to misusechange to ceftriaxone vial therapeutic failureIyophilized3nose bleeding, rash, tachycardia, dyspnea, electrolyteSide effectchange amphotericin B to liposomal type.			vomiting, bitter		
Azithromycin tab 1 therapeutic failure due to misuse Drug therapeutic failure due to misuse change to ceftriaxone vial therapeutic failure lyophilized 3 nose bleeding, tachycardia, dyspnea, electrolyte Side effect change amphotericin B to liposomal type.			taste		
Ivophilized 3 nose bleeding, dyspnea, Side effect change amphotericin B to liposomal type.	Azithromycin tab	1	therapeutic failure	Drug	change to ceftriaxone vial
lyophilized 3 nose bleeding, Side effect change amphotericin B to Amphotericin B rash, tachycardia, dyspnea, dyspnea, liposomal type.			due to misuse	failure	
Amphotericin B rash, tachycardia, dyspnea, electrolyte liposomal type.	lyophilized	3	nose bleeding,	Side effect	change amphotericin B to
dyspnea, electrolyte	Amphotericin B		rash, tachycardia,		liposomal type.
lelectrolyte			dyspnea,		
imbologoo			electrolyte		
Fluconazole 3 misuse to treat Drug stop fluconazole	Fluconazole	3	misuse to treat	Drug	stop fluconazole





Figure 3: Characteristics of patient cases (n=115).

Discussion

To the best of our knowledge, this is one of the few studies that demonstrate how a clinical pharmacist providing pharmaceutical care can help improve and maintain prescribing appropriateness in polypharmacy patients[3]. The current study reveals a high frequency of admissions related to drugs. The estimate contains some inherent flaws because some of the "possible" drug-related issues actually exist. As a result, the value of 15.65% for DTF is likely lower than the true rate of DRH, which is 84.34% due to ADR. As a result, about one-third of patients were admitted due to a symptom for which they were already receiving treatment; as a result, they might have experienced the negative effects of noncompliance. With very few exceptions, we have relied on a personal interview to determine our estimate of patient compliance[11].

There is considerable disagreement about the scope of the DRH problem, and published studies report widely disparate percentages. The findings indicate that variation in the intensity and quality of DRH monitoring is a significant source of variation. The data was gathered entirely on the basis of a general request that doctors and pharmacists report cases of DRH. A random sample of non-DRH cases revealed that this 'passive self-reporting' system missed at least one-third of cases that were later determined to be DRH[1, 11]. Finally, a doctor's perception of the term "drug-related" may differ significantly from that of the investigator; for example, a case of insulin-induced hypoglycemia was reportedly not drug-related, but rather "due to insufficient carbohydrate intake." Thus, it appears clear that a valid estimate of the DRH rate can only be obtained if data is collected by

someone who is qualified to evaluate each case independently, such as clinical pharmacists.

The general criteria for determining the causality of events presented a unique and challenging problem for NSAID-or aspirin-induced ulcers. A reasonable temporal relationship between the start of drug therapy and the onset of ADR symptoms is generally required for a probable ADR. In some cases, the patient had been taking an NSAID for so long that the cumulative risk of developing a spontaneous ulcer could not be ignored. We chose to disregard the long duration of therapy and make whether the patient had spontaneous ulcers the main factor in distinguishing between probable and possible drug-induced ulcers[13].

In addition, the current multifaceted intervention included patient education, pharmacist-led medication matchmaking, and collaborative care between the pharmacist and the patient's primary care physician. This was done to improve adherence to medication. Our findings also support previous studies on polypharmacy in ambulatory patients and the role of the clinical pharmacist in their healthcare delivery, demonstrating there aren't many significant drug interactions and therapeutic overlaps[14, 15].

Conclusion

According to this study, there were many discovered adverse drug events that led to their admission to the hospital. In some of these cases, the patient is the main cause due to non-compliance in using the prescribed drugs correctly or the use of some medicines inappropriately. There are other reasons, including errors made by doctors when writing some medications, which can result in therapeutic interactions or adverse drug reactions; or errors in calculating doses and routes of administration; and here this study emphasized the importance of involving clinical pharmacists in the health care of patients in the hospital emergency department for the purpose of discovering treatment errors and discussing them for the reducing cases of misuse of prescribed drugs. According to the findings of this study, clinical pharmacists play an important role in identifying drug inconsistencies and communicating this information in order to reduce their impact.

Limitation

Finally, because our research was limited to a single hospital with trained clinical pharmacists, only similar settings can apply to our findings. We were also unable to look further into factors related to doctors' and medication-related issues because of the small sample size of the patients studied.

Acknowledgments

The authors would like to thank the hospital staff, doctors, and pharmacists who assisted with data collection and outcome assessments for this study, as well as the patients and families who participated.

Ethical approval

The ethics committee at the University of Basra/Medical College and the clinical pharmacy section in the Basra health department approved the study design. The committee was enthusiastic about the project.

Conflicts of interest: The authors declare that they have no conflicts of interest.

References

- 1. Al-Arifi, M., et al., Emergency department visits and admissions due to drug related problems at Riyadh military hospital (RMH), Saudi Arabia. Saudi Pharmaceutical Journal, 2014. 22(1): p. 17-25.
- 2. Carter, B.L. and D.K. Helling, *Ambulatory care pharmacy services: the incomplete agenda*. Annals of Pharmacotherapy, 1992. 26(5): p. 701-708.
- Dewi, P. S., Ratini, N. N., & Trisnawati, N. L. P. (2022). Effect of x-ray tube voltage variation to value of contrast to noise ratio (CNR) on computed tomography (CT) Scan at RSUD Bali Mandara. International Journal of Physical Sciences and Engineering, 6(2), 82–90. https://doi.org/10.53730/ijpse.v6n2.9656
- 4. Graabæk, T., et al., *Pharmacist-led medication review in an acute admissions unit: a systematic procedure description.* European Journal of Hospital Pharmacy, 2015. 22(4): p. 202-206.
- 5. Hallas, J., et al., Drug related admissions to a cardiology department; frequency and avoidability. Journal of internal medicine, 1990. 228(4): p. 379-384.
- 6. Hallas, J., et al., *Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention.* Journal of internal medicine, 1990. 228(2): p. 83-90.
- 7. Hallas, J., et al., *Drug-related admissions to a department of medical gastroenterology: the role of self-medicated and prescribed drugs.* Scandinavian journal of gastroenterology, 1991. 26(2): p. 174-180.
- 8. Ho, P.M., et al., *Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial.* JAMA internal medicine, 2014. 174(2): p. 186-193.
- 9. Hohl, C.M., et al., *Do emergency physicians attribute drug-related emergency department visits to medication-related problems?* Annals of emergency medicine, 2010. 55(6): p. 493-502. e4.
- Jatau, A.I., et al., Prevalence of drug-related emergency department visits at a teaching hospital in Malaysia. Drugs-real world outcomes, 2015. 2(4): p. 387-395.
- 11. Majumdar, S.R., H.L. Lipton, and S.B. Soumerai, *Evaluating and improving physician prescribing*. Pharmacoepidemiology, 2005. 4: p. 419-438.
- 12. Montamat, S.C. and B. Cusack, *Overcoming problems with polypharmacy and drug misuse in the elderly.* Clinics in geriatric medicine, 1992. 8(1): p. 143-158.
- 13. Pemayun, C. I. B., & Martini, I. A. O. (2021). Implementation motivation, work discipline in work productivity of employees in the

11960

hospital. International Research Journal of Management, IT and Social Sciences, 8(6), 630-638. https://doi.org/10.21744/irjmis.v8n6.1961

- 14. Repp, K.L., et al., *Drug-related problems and hospital admissions in cardiac transplant recipients*. Annals of Pharmacotherapy, 2012. 46(10): p. 1299-1307.
- 15. Schnipper, J.L., et al., *Role of pharmacist counseling in preventing adverse drug events after hospitalization.* Archives of internal medicine, 2006. 166(5): p. 565-571.
- Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Get vaccinated when it is your turn and follow the local guidelines. *International Journal of Health Sciences*, 5(3), x-xv. https://doi.org/10.53730/ijhs.v5n3.2938
- 17. Thevelin, S., et al., *Development of a standardized chart review method to identify drug-related hospital admissions in older people.* British journal of clinical pharmacology, 2018. 84(11): p. 2600-2614.
- Thikra Etihad, M.M.A., Randomized clinical trial (RCT) of a clinical pharmacist intervention to reduce drug misuse and improve inappropriate prescribing in hospitalized patients in province of Al Basra. International Journal of Health Sciences / https://doi.org/10.53730/ijhs.v6nS2.8388, 2022. 6(SSN 2550-6978 E-ISSN 2550-696X): p. 12845–12852.